John A. Hey
Technik-/Wissenschafts-/F&E-Leiter bei ALZHEON, INC.
Profil
John A.
Hey is currently the Chief Scientific Officer at Alzheon, Inc. Prior to this, he was the Senior Director-Neurobiology at Schering-Plough Research Institute from 1988 to 2006.
He then served as the SVP-Discovery & Preclinical Drug Development at CoMentis, Inc. from 2006 to 2010, and as the Senior VP-Preclinical & Early Development at NormOxys, Inc. from 2010 to 2012.
Dr. Hey received his undergraduate degree from the University of Oklahoma.
Aktive Positionen von John A. Hey
| Unternehmen | Position | Beginn |
|---|---|---|
| ALZHEON, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von John A. Hey
| Unternehmen | Position | Ende |
|---|---|---|
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Corporate Officer/Principal | 01.01.2012 |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.01.2010 |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von John A. Hey
| University of Oklahoma | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Alzheon, Inc.
 Alzheon, Inc. BiotechnologyHealth Technology Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA. | Health Technology |
NormOxys, Inc.
NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Health Technology |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Health Technology |
